Efficacy and Safety Evaluation of Yangxin Dawaimixike Migao in the Treatment of Insomnia (Qi Stagnation and Blood Stasis Syndrome): a block randomized, double-blind, double simulation, positive-contro

适应症

试验速览

暂无简介。

•2. Those who meet the syndrome differentiation of TCM as Qi stagnation and blood stasis syndrome;
•3. Sleep quality PSQI score > 7 points;
•4. Insomnia Severity Index Scale score >= 8 points;
•5. Insomnia symptoms appear more than 3 times a week for more than 1 month;
•6. Persons aged 18 to 65 (including 18 and 65), regardless of gender;
•7. Voluntarily sign the informed consent form.

•1. Insomnia caused by certain physical diseases, organic diseases of the brain, and drug reactions;
•2. Insomnia caused by schizophrenia, depression, anxiety or other mental disorders; patients with HAMD score of 17 or more when enrolled; or total score of HAMA of 14 or more;
•3. Sleep disorders due to poor sleep hygiene, jet lag syndrome, shift work, and other irregular work schedules; sleep apnea syndrome, narcolepsy, and typical insomnia caused by other sleep disorders such as night terrors and nightmares;
•4. Combined liver and kidney damage, ALT, AST >= 1.5 times the upper limit of normal value, or Cr > the upper limit of normal value; combined with serious primary diseases such as hematopoietic system;
•5. Drug or alcohol dependent persons;
•6. People with allergies or allergies to this drug;
•7. Poor blood glucose control;
•8. Pregnant or intended pregnant or lactating women;
•9. Have used sleeping pills, antidepressants, anti-anxiety drugs or other drugs that affect the central nervous system in the last two weeks or psychological and physical therapy;
•10. Participants in other clinical trials in the past 3 months;
•11. Researchers consider others unsuitable for participants.

发起方